AusBiotech is Australia's Biotechnology Industry Organisation, dedicated to the development, growth and prosperity of the Australian Biotechnology Industry. We deliver initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for our sector nationally and around the world.
AusBiotech represents over 3,000 members working and studying in life sciences, including therapeutics, medical technology (devices and diagnostics), digital health, and agritech. With representation across the states our national network works to promote Australian research, translation, development, commercialisation and manufacturing in the national interest.
The structure is a not-for-profit limited guarantee company managed by a Board elected by members in line with its constitution.
We’ve reached 36,000 followers! 🎉
Thank you to everyone who’s joined us on this journey — from researchers and entrepreneurs to investors — united by a shared vision to grow Australia’s life sciences ecosystem.
AusBiotech connects innovators, supports commercialisation, and advocates for the policies and partnerships that enable our sector to thrive.
👉 Follow us to stay connected with the people, places, and ideas shaping the future of health.
Become a member: https://lnkd.in/gDzXcq_g#LifeSciences#Biotech#Medtech#Australia
𝗧𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮𝗻 𝗺𝗲𝗱𝘁𝗲𝗰𝗵 𝘀𝘁𝗮𝗿𝘁𝘀 𝘄𝗶𝘁𝗵 𝘆𝗼𝘂
Every breakthrough begins with a story, an idea, a challenge overcome, a lesson learned. 𝗡𝗼𝘄, 𝗶𝘁’𝘀 𝘆𝗼𝘂𝗿 𝘁𝘂𝗿𝗻 𝘁𝗼 𝘀𝗵𝗮𝗿𝗲 𝘆𝗼𝘂𝗿𝘀.
Australia’s medtech sector is at a defining moment. We’re tackling complex challenges in regulation, funding and access, while unlocking bold new possibilities in diagnostics, AI and sovereign manufacturing.
At 𝗔𝘂𝘀𝗠𝗲𝗱𝘁𝗲𝗰𝗵 𝟮𝟬𝟮𝟲 (𝟭𝟵–𝟮𝟭 𝗠𝗮𝘆, 𝗣𝗲𝗿𝘁𝗵), we’re bringing the brightest minds together to shape what comes next and your insight could be the spark that drives change.
📝 𝗦𝘂𝗯𝗺𝗶𝘁 𝘆𝗼𝘂𝗿 𝘀𝗲𝘀𝘀𝗶𝗼𝗻 𝗽𝗿𝗼𝗽𝗼𝘀𝗮𝗹 𝘁𝗼:
• Share your experience and ideas that make a difference
• Inspire collaboration across research, industry and government
• Position Australia as a global leader in medtech innovation
• Accelerate patient access to safe, effective and life-changing technologies
This is more than a conference. It’s a platform for progress and your voice belongs in the conversation!
𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀 𝗰𝗹𝗼𝘀𝗲 𝗙𝗿𝗶𝗱𝗮𝘆, 𝟮𝟭 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟱
Submit your session here: https://lnkd.in/dDTE3Qwq#AusMedtech2026#AM26#SessionProposal#Medtech#MedtechConference
AusBiotech was pleased to co-host a high-level roundtable: National Health and Medical Research Strategy (NHMRS) – Industry and Commercialisation Focus Session at the AusBiotech International Conference 2025.
The session brought together senior representatives from government, industry, and research to discuss practical actions outlined in Focus Area 4: 'Driving impact through research translation, innovation and commercial solutions' within the draft NHMRS and how this intersects with the Strategic Examination of Research and Development (SERD).
AusBiotech CEO Ms Rebekah Cassidy co-chaired the session alongside Ms Rosemary Huxtable AO PSM, Chair of the NHMRS, with Dr Kate Cornick, panel member for SERD, contributing key insights.
We thank all attendees, including representatives from the Department of Health and Aged Care (DoHA), SERD, the Department of Industry, Science and Resources (DISR) and MTPConnect for their valuable contributions to this solutions-focused discussion on advancing Australia’s research translation and commercialisation outcomes.
Australian Government Department of Health, Disability and Ageing#AusBiotech2025#LifeSciences#Biotech#Innovation#Collaboration
🌏 𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝗧𝗵𝗲 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮𝗻 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲 𝗛𝗮𝗻𝗱𝗯𝗼𝗼𝗸
Are you searching for a trusted partner to deliver your next clinical trial or scale your manufacturing? Choose Australia, where innovation meets reliability.
𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮’𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗮𝗻𝗱 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 𝗶𝘀 𝗿𝗲𝗰𝗼𝗴𝗻𝗶𝘀𝗲𝗱 𝗴𝗹𝗼𝗯𝗮𝗹𝗹𝘆 𝗳𝗼𝗿 𝗶𝘁𝘀:
⚙️ Efficient regulatory and ethics approvals under the TGA framework, aligned with major international standards.
👩🔬 Skilled investigators, diverse participant populations, and world-class research facilities.
🤝 Strong government support and R&D incentives that foster collaboration and accelerate development.
The result is a thriving environment where local and international innovators can develop, test and manufacture life-changing therapies with confidence. Yet for many organisations, navigating this growing ecosystem and finding the right partners can still be complex.
That is why AusBiotech has created The Australian Advantage Handbook, a new digital resource that brings together Australia’s leading clinical trial and manufacturing service providers in one trusted directory.
Launched during the AusBiotech International Conference 2025 as part of “The Australian Advantage: Unlocking Clinical Trials and Contract Manufacturing Excellence” stream, this handbook showcases the breadth of capability that positions Australia as a global hub for life sciences collaboration.
𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗛𝗮𝗻𝗱𝗯𝗼𝗼𝗸 𝘁𝗼 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 𝘄𝗵𝗼 𝗰𝗮𝗻 𝗵𝗲𝗹𝗽 𝘆𝗼𝘂𝗿 𝗻𝗲𝘅𝘁 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝘁𝗵𝗿𝗶𝘃𝗲 𝗶𝗻 𝗔𝘂𝘀𝘁𝗿𝗮𝗹𝗶𝗮’𝘀 𝗱𝘆𝗻𝗮𝗺𝗶𝗰 𝗹𝗶𝗳𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺.
📤Download the handbook here: https://lnkd.in/ddEhcgDg#AusBiotech#TheAustralianAdvantageHandbook#ClinicalTrials#Manufacturing#ClinicalResearch
Last week, AusBiotech hosted the Australia–United Kingdom BioBridge Breakfast in partnership with the British Consulate-General Melbourne, bringing together leaders from both nations’ life sciences sectors to discuss opportunities for collaboration under the Australia–UK Free Trade Agreement.
The event was held as part of Australia’s biggest week in biotech.
We thank all speakers, panellists, and attendees for contributing to this important bilateral dialogue:
• Michael Eyley, Incoming Consul Trade and Investment, British Consulate-General Melbourne
• Prof. Chris Molloy, CEO, Medicines Discovery Catapult
• Professor JOHN SKERRITT AM, AusBiotech Board Member and Former Head of the Therapeutic Goods Administration
• Rebekah Cassidy, CEO, AusBiotech (Moderator)
• Dr Felicia Pradera, Director, Regional Research Centre for Respiratory Medicines and Tropical Disease, Moderna
• Laurence Bishop PhD, Head of Business Development and Deputy Director, ApconiX
• Bruce Hamilton, Director, Drug Development & Regulatory Strategy, Labcorp
The BioBridge initiative represents a shared commitment to advancing cross-border research, development, and commercialisation — supporting stronger regulatory alignment and enabling biotech innovation across both countries.
#LifeSciences#Biotech#InternationalCollaboration#AustraliaUK#AusBiotech2025
Following the record-breaking attendance of the AusBiotech International Conference 2025 in Melbourne, AusBiotech is delighted that next year’s Conference will be held in Queensland.
The Queensland Government and Tourism and Events Queensland will be the Host State Partners for the AusBiotech Invest and AusBiotech International Conference 2026 and 2027 — the premier events on the Asia-Pacific region's life sciences calendar.
These flagship events of Australia’s biggest week in biotech convene the full breadth of the life sciences ecosystem and connect partners from around the world.
Deputy Premier and Minister for State Development, Infrastructure and Planning Jarrod Bleijie MP announced the news at AusBiotech International Conference 2025, calling the announcement a strategic win for Queensland: “Biomedical is a priority industry for the Crisafulli Government — and hosting the AusBiotech International Conference and AusBioInvest will help us showcase our strengths, attract global investment, strengthen our international partnerships, and grow our sovereign capability.
“These events will be hosted in Brisbane and the Gold Coast, showcasing not only our cutting-edge biomedical capabilities but our enviable lifestyle as well."
AusBiotech CEO Rebekah Cassidy said: “As the peak body representing and convening Australia’s thriving life sciences sector, AusBiotech is proud to unite our national innovation ecosystem and connect it with the world.
"Taking the AusBiotech Invest and AusBiotech International Conferences to Queensland for two consecutive years highlights Queensland’s focus on becoming a hub for life sciences innovation.”
Following two successful years in Victoria, Australia’s biggest week in biotech will head north — to the Gold Coast in 2026 and Brisbane in 2027 — showcasing Queensland’s growing strength as a global hub for biomedical innovation and commercialisation.
We sincerely thank the Victorian Government for their partnership and support as our Host State Partner for the past two years.
Read more here: https://lnkd.in/gqV3MtHv#AusBiotech2026#LifeSciences#Biotech#Medtech#Queensland
AusBiotech’s Industry Growth Program (IGP) took to the BioInnovation Spotlight Stage at the AusBiotech International Conference 2025, and participated in our Innovation Activation Commercialisation Masterclass at AusBiotech Invest 2025 — part of Australia’s biggest week in biotech.
As an Industry Partner Organisation (IPO) under the Australian Government's Industry Growth Program, AusBiotech delivers commercialisation advisory support for Australian biotech and medtech companies advancing through the program.
At AusBiotech 2025, the IGP cohort presented to a record-breaking audience. This year's conference had more than 1,800 delegates attending throughout the week. AusBiotech Invest featured live Shark Tank-style pitches, investor insights, and leadership panels focused on commercialising Australian innovation and strengthening global readiness.
A big thank you to our speakers, judges, and panellists:
🔹 Dr Nick Pachuda and Britt Koth, Precision Life Sciences & Neovate Capital (US)
🔹Helen Mutimer, Head of IP Advisory, FB Rice
🔹Dave Whelan, Bespoke Strategy (US)
🔹Mike Sewell and Robin Fieldhouse, Industry Growth Program Advisors
🔹Hayley van der Meer, Director of Membership, AusBiotech
🔹Keith Calvert, Director, Industry Growth Program
🔹Mark Harding Senior Vice President Global Marketing R&D
🔹Samantha South, Commercialisation Manager, Research Development and Innovation, Reliis
🔹Dr Marthe D'Ombrain D’Ombrain, Executive Director & Head of Global Research Innovation, CSL and AusBiotech Board member
Congratulations to all pitching companies for their outstanding presentations across the week.
Led by Tamlyn O'Connor it was an inspiring week connecting innovators across the life sciences ecosystem — driving translation, development, and commercialisation from research to real-world impact.
#AusBiotech2025#LifeSciences#Biotech#Innovation#InvestmentDepartment of Industry, Science and Resources Australian Government
Australia’s biggest week in biotech has come to a close!
Across two of our flagship conferences AusBiotech Invest 2025 and AusBiotech International Conference 2025, we brought together the sector for the conversations that matter. This year saw record-breaking attendance, speakers, sessions, exhibitors and AusPartnering meetings.
A huge thank you to everyone who joined us in Melbourne and to our Host State Partner, the Victorian Government. We can’t wait to see you next year!
What were your highlights? Share them in the comments! 👇
#AusBiotech2025#Biotech#LifeSciences#BiggestWeekInBiotech
We asked delegates to describe the energy of this year’s AusBiotech International Conference, and the top responses were 'COLLABORATION', 'WORLD-CLASS', and 'INTERNATIONAL' — and we couldn’t agree more.
With delegates from more than 20 countries, 250+ speakers, and 130 exhibitors, this is the place to be if you’re in biotechnology and want to connect with the broader life sciences ecosystem.
As the week draws to a close, conversations have spanned global trends, investment and partnerships, advanced therapeutics, AI deployment, sustainability and more — reflecting the global shifts and emerging opportunities shaping Australia’s biotech future.
At AusBiotech, we’re proud to convene this super-connector conference, uniting Australian expertise with local and global partners to shape what’s next for our sector.
Rebekah CassidyTelix Pharmaceuticals LimitedAmanda Caples#AusBiotech2025#LifeSciences#Biotech#Medtech#Innovation
